Kaplan Alesia, Sackett Katie, Sumstad Darin, Kadidlo Dianne, McKenna David H
Department of Pathology, University of Pittsburgh School of Medicine.
Institute for Transfusion Medicine, Pittsburgh, Pennsylvania.
Transfusion. 2017 Sep;57(9):2216-2219. doi: 10.1111/trf.14192. Epub 2017 Jun 26.
Mesenchymal stem cells (MSCs) continue to be investigated in multiple clinical trials as potential therapy for different disorders. There is ongoing controversy surrounding the clinical use of cryopreserved versus fresh MSCs. However, little is known about how cryopreservation affects marrow as starting material. The growth kinetics of MSC cultures derived from fresh versus cryopreserved marrow were compared.
Data were reviewed on the growth kinetics of MSCs derived from fresh versus cryopreserved marrow of nine donors. Marrow harvested from each donor was separated into four aliquots (one fresh and three cryopreserved for culture). Data on the date of mononuclear cell cryopreservation/thaw, MSC counts at Passages 1 and 2, MSC doubling, MSC fold expansion, viability (of mononuclear cells and final MSCs), and on flow cytometry markers of mononuclear cells and final MSCs were analyzed for the fresh and cryopreserved marrow groups.
In total, 21 MSC lots (seven fresh and 14 cryopreserved) were obtained. The average age of cryopreserved mononuclear cell product was 295 days (range, 18-1241 days). There were no significant differences between MSC numbers at Passage 1 (p = 0.1), final MSC numbers (p = 0.5), MSC doubling (p = 0.7), or MSC fold expansion (p = 0.7). A significant difference was observed in viability by flow cytometry for both mononuclear cells (p = 0.002) and final MSCs (p = 0.009), with higher viability in the fresh marrow group.
This study demonstrates that MSCs derived from cryopreserved marrow have the same growth characteristics as fresh marrow-derived MSCs. Further studies are needed to explore potential differences in clinical efficacy.
间充质干细胞（MSCs）作为不同疾病的潜在治疗方法，仍在多项临床试验中接受研究。关于冷冻保存的MSCs与新鲜MSCs的临床应用，目前仍存在争议。然而，对于冷冻保存如何影响作为起始材料的骨髓，人们知之甚少。本研究比较了源自新鲜骨髓与冷冻保存骨髓的MSCs培养物的生长动力学。
回顾了9名供体新鲜骨髓与冷冻保存骨髓来源的MSCs生长动力学数据。从每个供体采集的骨髓被分成4份（1份新鲜的和3份用于培养的冷冻保存的）。分析新鲜骨髓组和冷冻保存骨髓组关于单核细胞冷冻保存/解冻日期、第1代和第2代时的MSCs计数、MSCs倍增、MSCs扩增倍数、（单核细胞和最终MSCs的）活力以及单核细胞和最终MSCs的流式细胞术标记的数据。
总共获得了21个MSCs批次（7个新鲜的和14个冷冻保存的）。冷冻保存的单核细胞产物的平均保存时间为295天（范围为18 - 1241天）。第1代时的MSCs数量（p = 0.1）、最终MSCs数量（p = 0.5）、MSCs倍增（p = 0.7）或MSCs扩增倍数（p = 0.7）之间均无显著差异。通过流式细胞术观察到，单核细胞（p = 0.002）和最终MSCs（p = 0.009）的活力存在显著差异，新鲜骨髓组的活力更高。
本研究表明，源自冷冻保存骨髓的MSCs与源自新鲜骨髓的MSCs具有相同的生长特性。需要进一步研究以探索临床疗效方面的潜在差异。
